Maximising the potential of AKT inhibitors as anti-cancer treatments.
Loading...
Embargo End Date
ICR Authors
Authors
Brown, JS
Banerji, U
Banerji, U
Document Type
Journal Article
Date
2017-04-01
Date Accepted
2016-11-16
Abstract
PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting AKT is therefore a highly attractive anti-cancer strategy with multiple AKT inhibitors now in various stages of clinical development. In this review, we summarise the role and regulation of AKT signalling in normal cellular physiology. We highlight the mechanisms by which AKT signalling can be hyperactivated in cancers and discuss the past, present and future clinical strategies for AKT inhibition in oncology.
Citation
Pharmacology & therapeutics, 2017, 172 pp. 101 - 115
Source Title
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
ISSN
0163-7258
eISSN
1879-016X
Collections
Research Team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Medicine Drug Development Unit (de Bono)